Scienture Holdings Inc SCNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Scienture Holdings, Inc. Announces Reverse Stock Split
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
Trading Information
- Previous Close Price
- $2.99
- Day Range
- $2.73–3.00
- 52-Week Range
- $2.64–18.75
- Bid/Ask
- $2.51 / $2.95
- Shares Outstanding
- 1.79M
- Market Cap
- $4.53M
- Volume/Avg
- 15,460 / 153,391
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.36
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.scienture.com
Valuation
Metric | SCNX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.00 |
Price/Sales | 2.36 |
Price/Cash Flow | — |
Price/Earnings
SCNX
Financial Strength
Metric | SCNX |
|---|---|
Quick Ratio | 0.92 |
Current Ratio | 1.10 |
Interest Coverage | −25.20 |
Quick Ratio
SCNX
Profitability
Metric | SCNX |
|---|---|
Return on Assets (Normalized) | −15.23% |
Return on Equity (Normalized) | −19.77% |
Return on Invested Capital (Normalized) | −17.15% |
Return on Assets
SCNX
Pharmaceutical Retailers Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| JD Health International Inc JDHIF | — | LOCK|<Hp% | $17B | |||
| JD Health International Inc ADR JDHIY | — | LOCK|^#@m@ | $17B | |||
| Alibaba Health Information Technology Ltd ALBHF | — | LOCK|R&^< | $6B | |||
| Alibaba Health Information Technology Ltd ADR ALBBY | — | LOCK|#bq!q | $6B | |||
| Raia Drogasil SA ADR RADLY | — | LOCK|^$ | $4B | |||
| Sugi Holdings Co Ltd SGIPF | — | LOCK|?W$ | $3B | |||
| COSMOS Pharmaceutical Corp CSMYF | — | LOCK|FY | $3B | |||
| Clicks Group Ltd ADR CLCGY | — | LOCK|#b>^ | $3B | |||
| Clicks Group Ltd CCKRF | — | LOCK|yrfX | $3B | |||
| Redcare Pharmacy NV ADR SAEYY | — | LOCK|<% | $2B |